Shilpa Medicare Limited (SHILPAMED.BO)
INR 643.55
(5.66%)
INR 643.55
(5.66%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.58 Billion INR | 114.3% |
| 2022 | 1.19 Billion INR | -48.43% |
| 2021 | 2.26 Billion INR | 12.16% |
| 2020 | 2.72 Billion INR | -12.51% |
| 2019 | 2.36 Billion INR | 39.17% |
| 2018 | 1.88 Billion INR | -1.09% |
| 2017 | 1.83 Billion INR | -8.06% |
| 2016 | 1.86 Billion INR | 8.62% |
| 2015 | 1.67 Billion INR | 22.96% |
| 2014 | 1.33 Billion INR | 9.05% |
| 2013 | 1.22 Billion INR | 64.67% |
| 2012 | 737.74 Million INR | 7.65% |
| 2011 | 693.74 Million INR | -11.5% |
| 2010 | 789.63 Million INR | 2.11% |
| 2009 | 763.53 Million INR | 137.59% |
| 2008 | 321.36 Million INR | 72.79% |
| 2007 | 185.99 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 735.98 Million INR | 5.54% |
| 2023 Q1 | 481.87 Million INR | 28.81% |
| 2023 Q3 | 670.92 Million INR | 11.45% |
| 2023 FY | - INR | 114.3% |
| 2023 Q4 | 700.58 Million INR | 4.42% |
| 2023 Q2 | 601.98 Million INR | 24.93% |
| 2022 Q2 | 143.89 Million INR | -48.5% |
| 2022 Q4 | 374.1 Million INR | 8.9% |
| 2022 FY | - INR | -48.43% |
| 2022 Q1 | 279.38 Million INR | -67.15% |
| 2022 Q3 | 343.52 Million INR | 138.74% |
| 2021 FY | - INR | 12.16% |
| 2021 Q2 | 532.97 Million INR | 60.91% |
| 2021 Q1 | 331.21 Million INR | 66.34% |
| 2021 Q3 | 498.1 Million INR | -6.54% |
| 2021 Q4 | 850.59 Million INR | 70.77% |
| 2020 Q3 | 291.07 Million INR | -62.61% |
| 2020 FY | - INR | -12.51% |
| 2020 Q1 | 706.07 Million INR | 62.38% |
| 2020 Q2 | 778.54 Million INR | 10.26% |
| 2020 Q4 | 199.11 Million INR | -31.59% |
| 2019 Q4 | 434.83 Million INR | -44.02% |
| 2019 Q2 | 731.42 Million INR | 134.91% |
| 2019 FY | - INR | 39.17% |
| 2019 Q1 | 311.36 Million INR | -24.94% |
| 2019 Q3 | 776.81 Million INR | 6.2% |
| 2018 Q2 | 376.13 Million INR | -29.86% |
| 2018 FY | - INR | -1.09% |
| 2018 Q3 | 293.27 Million INR | -22.03% |
| 2018 Q1 | 536.24 Million INR | 1.79% |
| 2018 Q4 | 414.84 Million INR | 41.45% |
| 2017 FY | - INR | -8.06% |
| 2017 Q3 | 313.76 Million INR | -42.27% |
| 2017 Q2 | 543.48 Million INR | 34.95% |
| 2017 Q1 | 402.74 Million INR | -37.45% |
| 2017 Q4 | 526.83 Million INR | 67.91% |
| 2016 Q1 | 294.7 Million INR | -48.85% |
| 2016 FY | - INR | 8.62% |
| 2016 Q4 | 643.83 Million INR | 82.95% |
| 2016 Q3 | 351.91 Million INR | -39.37% |
| 2016 Q2 | 580.43 Million INR | 96.96% |
| 2015 Q4 | 576.14 Million INR | 31.34% |
| 2015 FY | - INR | 22.96% |
| 2015 Q1 | 284.17 Million INR | -26.28% |
| 2015 Q2 | 426.03 Million INR | 49.92% |
| 2015 Q3 | 438.65 Million INR | 2.96% |
| 2014 Q2 | 298.64 Million INR | -2.16% |
| 2014 FY | - INR | 9.05% |
| 2014 Q4 | 385.49 Million INR | 11.84% |
| 2014 Q3 | 344.67 Million INR | 15.41% |
| 2014 Q1 | 305.24 Million INR | -14.11% |
| 2013 Q2 | 254.11 Million INR | -1.41% |
| 2013 FY | - INR | 64.67% |
| 2013 Q4 | 355.37 Million INR | -0.18% |
| 2013 Q3 | 356.01 Million INR | 40.1% |
| 2013 Q1 | 257.75 Million INR | 35.27% |
| 2012 FY | - INR | 7.65% |
| 2012 Q2 | 197.58 Million INR | 9.5% |
| 2012 Q3 | 174.21 Million INR | -11.82% |
| 2012 Q1 | 180.43 Million INR | -23.43% |
| 2012 Q4 | 190.54 Million INR | 9.37% |
| 2011 FY | - INR | -11.5% |
| 2011 Q1 | 166.37 Million INR | 0.0% |
| 2011 Q4 | 235.64 Million INR | 88.95% |
| 2011 Q3 | 124.71 Million INR | -7.79% |
| 2011 Q2 | 135.25 Million INR | -18.7% |
| 2010 FY | - INR | 2.11% |
| 2009 FY | - INR | 137.59% |
| 2008 FY | - INR | 72.79% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 73.089% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 95.811% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 62.29% |
| Granules India Limited | 8.6 Billion INR | 69.921% |
| Indoco Remedies Limited | 2.64 Billion INR | 2.232% |
| Achyut Healthcare Limited | 524 Thousand INR | -493789.885% |
| Ajanta Pharma Limited | 12.56 Billion INR | 79.404% |
| Alkem Laboratories Limited | 24.19 Billion INR | 89.304% |
| Alpa Laboratories Limited | 86.12 Million INR | -2904.845% |
| Brooks Laboratories Limited | 41.72 Million INR | -6102.03% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -9.809% |
| Bajaj HealthCare Limited | 444.51 Million INR | -482.202% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -74.978% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 97.068% |
| Eris Lifesciences Limited | 6.98 Billion INR | 62.957% |
| FDC Limited | 4.4 Billion INR | 41.205% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 77.186% |
| Gufic Biosciences Limited | 1.48 Billion INR | -74.806% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 62.283% |
| Ipca Laboratories Limited | 13.29 Billion INR | 80.541% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -700.094% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 3228.341% |
| Lasa Supergenerics Limited | -65.08 Million INR | 4076.618% |
| Laurus Labs Limited | 8 Billion INR | 67.674% |
| Lupin Limited | 36.96 Billion INR | 93.0% |
| Mankind Pharma Limited | 28.09 Billion INR | 90.788% |
| Medicamen Biotech Limited | 245.66 Million INR | -953.482% |
| Medico Remedies Limited | 150.37 Million INR | -1620.985% |
| Megasoft Limited | 284.73 Million INR | -808.922% |
| NATCO Pharma Limited | 18.79 Billion INR | 86.23% |
| Piramal Pharma Limited | 13.05 Billion INR | 80.177% |
| RPG Life Sciences Limited | 1.28 Billion INR | -101.95% |
| Sigachi Industries Limited | 883.39 Million INR | -192.958% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.13% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 44.668% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -501.47% |
| Unichem Laboratories Limited | 742.35 Million INR | -248.618% |
| Wanbury Limited | 985.49 Million INR | -162.609% |
| Windlas Biotech Limited | 781.72 Million INR | -231.063% |
| ZIM Laboratories Limited | 462.09 Million INR | -460.052% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 95.397% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 169.359% |
| Divi's Laboratories Limited | 25.43 Billion INR | 89.823% |
| Hester Biosciences Limited | 539.47 Million INR | -379.727% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 14.146% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -279.171% |
| Bal Pharma Limited | 345.59 Million INR | -648.855% |
| Strides Pharma Science Limited | 3.76 Billion INR | 31.256% |
| Venus Remedies Limited | 711.8 Million INR | -263.582% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 33.801% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -65.494% |
| Aarti Drugs Limited | 3.24 Billion INR | 20.336% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 0.714% |
| Suven Life Sciences Limited | -992.78 Million INR | 360.68% |
| Ind-Swift Limited | 1.06 Billion INR | -142.988% |
| Valiant Laboratories Limited | 12.73 Million INR | -20215.433% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 72.276% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 191.711% |
| Themis Medicare Limited | 562.6 Million INR | -359.998% |
| Hikal Limited | 2.69 Billion INR | 3.872% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 92.608% |
| Sequent Scientific Limited | 549.8 Million INR | -370.714% |
| Novartis India Limited | 1.26 Billion INR | -103.891% |
| Wockhardt Limited | 1.08 Billion INR | -139.628% |
| Jubilant Pharmova Limited | 8 Billion INR | 67.674% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -19713.068% |
| Neuland Laboratories Limited | 4.74 Billion INR | 45.495% |
| Morepen Laboratories Limited | 1.72 Billion INR | -49.945% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -800.403% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -1379.304% |